> Skip repeated content
photo of Kyriakos A. Kirou, MD, DSc, FACP

Kyriakos A. Kirou, MD, DSc, FACP


About Dr. Kirou


Dr. Kyriakos A. Kirou, Assistant Attending Physician at Hospital for Special Surgery, is a physician-scientist in the field of academic rheumatology. He has a special interest in the research and treatment of systemic autoimmune rheumatic diseases, such as systemic lupus erythematosus.


Special Expertise

Systemic Lupus Erythematosus (SLE)
Lupus Nephritis
Lupus and Pregnancy
Anti-phospholipid Syndrome
Rheumatoid Arthritis
Psoriatic Arthritis 
Systemic Sclerosis

Physician Video

Patient Stories


American College of Rheumatology, Fellow
American College of Physicians, Fellow
Arthritis Foundation Member, Member
Hellenic Medical Society of New York, Member
New York Rheumatism Association, Member
National Psoriasis Foundation, Member

Patient ratings for Dr. Kirou


Learn more about our patient ratings.


Please do not hesitate to contact our office if you have questions regarding your insurance coverage. You may have coverage subject to the availability of 'out-of-network' benefits.



Director, Lupus Nephritis Program, Hospital for Special Surgery
Clinical Co-Director, Mary Kirkland Center for Lupus Care, Hospital for Special Surgery
Associate Attending Physician, Hospital for Special Surgery
Assistant Scientist, Hospital for Special Surgery
Associate Attending Physician, NewYork-Presbyterian Hospital/Weill Cornell
Assistant Clinical Member, Memorial Sloan-Kettering Cancer Center
Associate Professor of Clinical Medicine, Weill Cornell Medical College


MD, Aristotle University of Thessaloniki, Greece
DSc, National University of Athens, Greece


Internal Medicine, New York Hospital of Queens, Flushing, New York


Rheumatology, Hospital for Special Surgery


American Board of Internal Medicine, 1995, 2005
American Board of Rheumatology, 1998, 2008


HSS Division of Rheumatology Teaching Excellence Award, 2007 
ACR Annual Slide Competition, Third Place, 2006
NIAID/NIH Mentored Clinical Scientist Development Award (KO8), 2003
ACR/REF Global Arthritis Research Network Travel Grant, 2002
Merck 2000 Rheumatology Young Investigator, 2000
Extended Fellowship Grant Award (3 years), The SLE Foundation Inc., 1999
Fellowship Grant Award, Arthritis Foundation, New York Chapter, 1998 
ACR/REF Travel Award, 1998

State Licensure




Patient Education by Dr. Kirou on HSS.edu

Blog Posts by Dr. Kirou

Selected Publications

Systemic Lupus Erythematosis: Understanding and Managing Renal Involvement - Featuring Kyriakos A. Kirou, MD, DSc, NewYork-Presbyterian Nov/Dec 2014 Newsletter, Advances in Rheumatology

Anti-interferon alpha treatment in SLE - Kyriakos A. Kirou, MD, Clinical Immunology (2013) 148, 303–312 2013 Elsevier Inc.

Pan N. Amigues I, Lyman S, Duculan R, Aziz F, Crow M, Kirou K. A surge in anti-dsDNA titer predicts a severe lupus flare within six months. Lupus. 2014;23(3):293-8. doi: 10.1177/0961203313515763. Epub 2013 Dec 6.

Kirou KA, Gkrouzman E. Anti-interferon alpha treatment in SLE. Clin Immunol. 2013 Sep;148(3):303-12. doi: 10.1016/j.clim.2013.02.013. Epub 2013 Mar 1. Review

Gulati CM, Satlin MJ, Magro CM, Kirou KA. Two systemic lupus erythematosus patients with severe pleurisy: similar presentations, different causes. Arthritis Care Res (Hoboken). 2013 Jun;65(6):1005-13. doi: 10.1002/acr.21988. No abstract available

Kalunian KC, Chatham WW, Massarotti EM, Reyes-Thomas J, Harris C, Furie RA, Chitkara P, Putterman C, Gross RL, Somers EC, Kirou KA, Ramsey-Goldman R, Hsieh C, Buyon JP, Dervieux T, Weinstein A. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis Rheum. 2012 Dec;64(12):4040-7. doi: 10.1002/art.34669.

Kirou KA, Gkrouzman E, Chevalier JM, Seshan SV. Anti-inflammatory strategies, not just B cell depletion, are required for optimal therapy for severe proliferative lupus nephritis: comment on the article by Rovin et al. Arthritis Rheum. 2012 Oct;64(10):3486; author reply 3486. doi: 10.1002/art.34617. No abstract available.

Kalliolias GD, Kirou KA. Type I interferons as biomarkers in autoimmune diseases. Biomark Med. 2012 Apr;6(2):137-40. doi: 10.2217/BMM.12.8. No abstract available.

Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B; Lupus Interferon Skin Activity (LISA) Study Investigators. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov;70(11):1905-13. doi: 10.1136/ard.2010.144485. Epub 2011 Jul 27.

Merrill JT, Wallace DJ, Petri M, Kirou KA,Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon {alpha} monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomized study. Annals of the rheumatic diseases, 2011

Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Kloiber S, Kirou KA, Lyman S, Crow MK. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Annals of the rheumatic diseases, 2011. 70(6): p. 1003-9

Robinson T, Kariuki SN, Franek BS, Kumabe M, Kumar AA, Badaracco M, Mikolaitis RA, Guerrero G, Utset TO, Drevlow BE, Zaacks LS, Grober JS, Cohen LM, Kirou KA, Crow MK, Jolly M, Niewold TB. Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-alpha and serologic autoimmunity in lupus patients. Journal of immunology, 2011. 187(3): p. 1298-303

Cherian J, Duculan R, Amigues I, Crow MK, Kirou KA. A 26-year-old white man with a systemic lupus erythematosus flare and acute multiorgan ischemia: Vasculitis or thrombosis? Arthritis care & research, 2011. 63(5): p. 766-74.

Kirou KA and Kalliolias GD. A new tool for detection of type I interferon activation in systemic lupus erythematosus. Arthritis Res. Ther. 12: 138; 2010

Thurlings RM, Boumans M, Tekstra J, van Roon JA, Vos K, van Westing DM, van Baarsen LG, Bos C, Kirou KA, Gerlag DM, Crow MK, Bijlsma JW, Verweij CL, Tak PP. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum. 2010 Dec;62(12):3607-14. doi: 10.1002/art.27702

For more publications, please see the PubMed listing.


Dr. Kyriakos Kirou has been very active in the translational and clinical research of systemic lupus erythematosus (SLE). Our approach has been the close comparison of carefully collected clinical with gene expression data from patients. In particular, we have investigated the role of type I IFN in the pathogenesis of lupus, but also in scleroderma (systemic sclerosis). We have found that the activation of the type I IFN pathway in SLE is independently associated with the presence in the blood of autoantibodies against RNA-binding proteins (RBP), renal disease, serologic activity of the disease, disease-related damage and failure to treat with antimalarial medications. Similar findings were noted in scleroderma. We are currently investigating other candidate biomarkers for lupus disease activity and damage.

Clinical Trials

Industry Relationships

Industry Relationships

One of the goals of HSS is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.

As part of the disclosure process, this website lists physician collaborations with outside companies. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.

As of November 13, 2019, Dr. Kirou reported no relationships with healthcare industry.

By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.

Dr. Kirou in the News